Title : Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1.

Pub. Date : 2020 Jun 9

PMID : 32444490






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS Metformin has been reported as a potentially novel antitumor agent in many experiments, but its therapeutic activity is discrepant and controversial so far. Metformin epidermal growth factor receptor Homo sapiens